Depressive symptoms and disability in acute patients with comorbidities in departments of internal medicine

Disturbi depressivi e disabilità in pazienti pluripatologici ricoverati in medicina interna

Salvatore La Carrubba a,*, Loredana Manna a, Carmelina Rinollo a, Antonino Mazzone b, Gualberto Gussoni c, Salvatore Di Rosa a, on behalf of the DIMIS Study researchers of Italian Federation of Internal Medicine (FADOI)

a Department of Internal Medicine, Villa Sofia Whitaker Hospital, Palermo, Italy
b Department of Internal Medicine, Legnano Hospital, Italy
c FADOI (Italian Federation of Internal Medicine) Study Centre

Received 19 April 2011; accepted 26 July 2011
available online 13 September 2011

KEYWORDS
Depression; Comorbidity; Disability.

Summary
Introduction: There are few data on the prevalence of depression among acute patients with comorbidities. The current study aimed to determine the prevalence of depressive symptoms in hospitalized patients admitted to Internal Medicine Units and the correlation between these symptoms and comorbidities and disability indexes.

Materials and methods: All consecutive patients admitted to 26 Internal Medicine Units of the Italian National Public Health System in Sicily, Italy, from September 2001 to March 2002 were screened. Within 24 hours of admission, patients were administered the Geriatric Depression Scale (GDS), Mini-Mental State Examination, Activities of Daily Living (ADL), Instrumental Activities of Daily Living (IADL) and Charlson’s Comorbidity Index.

Results: 1,947 subjects were included in the analyses. Of the patients, 509 (26.1%) showed depressive symptoms (indicated by GDS score ≥ 15). Depression was significantly associated (univariate analyses) with hypertension (OR 1.45; CI 95% 1.18-1.79), diabetes (OR 1.48, CI 95% 1.17-1.87), cerebrovascular disease (OR 1.50, CI 95% 1.08-2.07), cirrhosis (OR 1.49, CI 95% 1.01-2.19), ADL score (OR 0.72: CI 95% 0.63-0.82), and IADL score (OR 0.83; CI 95% 0.78-0.87), but not...
Introduction

It has been estimated that by the year 2020, the burden of depression will increase to 5.7% of the diseases, becoming the second leading cause of disability-adjusted life years lost [1]. In Europe, the annual cost of depression was estimated at Euro 118 billion in 2004 [2]. In Italy, the prevalence of the disease in the community and in primary care ranges from 8 to 11% [3,4]. A recent survey on hospitalized patients with chronic disease and previous studies on subjects with heart failure or other cardiovascular diseases suggest that depressive symptoms lead to worse clinical outcomes [5–11]. Symptoms of depression and anxiety also emerged as significant risk factors for the onset of type 2 diabetes [12]. Moreover, several studies showed a close link between depression and the risk of cardiovascular mortality [13–17]. Nevertheless, many results on this issue have been called into question [18,19], and the cause of increased risk of mortality is not fully understood [20]. The correlation between depression and comorbidities may be influenced by a proinflammatory state, but few data are available on this topic [21,22].

Screening for depression has been recognized as a useful tool for preventing persistent depression; however, it is not clear whether treatment improves clinical outcomes [23–27]. Despite these research findings, depression is underdiagnosed and undertreated by nonpsychiatric practitioners. In addition, few data are available about the prevalence of depression in acute patients with comorbidities hospitalized in departments of internal medicine [28].

The current study aimed to determine the prevalence of depressive symptoms among patients admitted into Internal Medicine Units and the correlation between these symptoms and comorbidities.

Materials and methods

The present analysis is part of an observational multicenter study (The DIMIS study - Depressione In Medicina Interna in Sicilia) that includes 26 Internal Medicine Units of the National Public Health System in Sicily, Italy. The study was conducted under the endorsement and scientific coordination of the Italian Federation of Internal Medicine (FADOI).

The primary goal of the DIMIS is to evaluate the prevalence of depression in acute patients hospitalized in departments of internal medicine and the association between depression, comorbidities, and health functional state. From September 2001 to March 2002, all subjects ≥ 20 years old who were consecutively admitted to the hospital were screened. Patients were administered the Mini-Mental State Examination (MMSE), a complete clinical examination with a cognitive assessment. The scores for this examination range from 0 to 30 points. In order to exclude subjects with severe cognitive impairment, patients with a score < 22 were not considered for the analyses [29,30]. Within 24 hours from admission, eligible patients completed the 30-item Geriatric Depression Scale (GDS), one of the most commonly used self-rating depression scales in geriatric populations [31]. The scale comprises 30 easy-to-use items, with answers in yes/no format, and it is designed to exclude the somatic symptoms of depression that are also observed in non-depressed elderly people [31,32]. A cut-off score of 11 on the GDS yields an 84% sensitivity rate and a 95% specificity rate for depression, whereas a cut-off score of 14 yields a slightly lower sensitivity rate of 80%, but a 100% specificity rate [32,33]. The GDS has been validated in geriatric medical outpatients, day-treatment patients, and younger subjects [34–38].

In the present study, the GDS was scored with two methods. In accordance with the above mentioned cut-off values [32,33], we first defined patients as "not depressed" (GDS < 15) or "depressed" (GDS ≥ 15). Further, subjects were stratified using a "screening score". In accordance with the original classification of Brink and Yesavage, patients were defined as "normal" (GDS < 10), "screened for mild depression" (GDS score between 10 and 19) or "screened for severe depression" (GDS score ≥ 20) [31,32].

The burden of cumulative comorbidities was calculated using the validated Charlson’s method, a weighted index that takes into account the number and the severity of comorbid conditions [39]. An index of "0" has been associated with a 12% 1-year expected mortality rate, while scores of "1–2" / "3–4" and "5" have been associated with 1-year expected mortality rates of 26%, 52% and 59%, respectively [39].

The degree of disability was evaluated using the Katz’s Activities of Daily Living (ADL) score and the Brody’s Instrumental Activities of Daily Living (IADL) score [40,41]. ADL yields a score (ranging from 0 to 6) based on the personal care tasks of bathing and washing, dressing, feeding, getting in and out of bed, getting to and from the toilet, and continence management [40]. IADL yields a score (ranging from 0 to 8) based on domestic tasks such as shopping, laundry, vacuuming, cooking a main meal and handling personal affairs.

Data management and statistical analyses

In the present work, categorical variables are presented as percentages and continuous variables are presented as mean ± standard deviation (SD) or as median and interquartile range (IQR), when appropriate. The GDS score was analyzed using the non-parametric Mann-Whitney U test. The correlations between Charlson’s score, MMSE, ADL, IADL, age and GDS score were analyzed using the Spearman’s Rho index.
The primary study objective was to identify predictors for a prognostic model of depression (indicated by GDS ≥ 15). To accomplish this, a set of pre-specified covariates were investigated with univariate logistic regression models. In addition, variables deemed to be clinically relevant were subsequently tested in a multivariate analysis regardless of their univariate findings and using the conventional rule of thumb (no less than ten events for each covariate). Results were reported as odds ratios with 95% confidence intervals. The association between depression (indicated by GDS ≥ 15 or as "screened score") and other categorical variables (previous diagnosis of depression, use of drugs) was evaluated by Chi-Square test. A two-tailed p value < 0.05 was considered statistically significant. All data were analyzed using SPSS software (version 12.1; SPSS, Inc., Chicago, Illinois).

Results

Of the 2,944 screened patients, 537 (18.2%) were excluded from the analysis because of severe cognitive impairment (MMSE < 22), 224 (7.6%) declined the interview, 76 (2.6%) had incomplete data, and 264 (9.0%) did not have the GDS submitted within 24 hours of admission. Therefore, data from 1,947 (66.1%) patients were analyzed (mean age 59.8 ± 16 years, ranging from 20 to 90; 961 men (mean age 59.9 ± 16 years) and 986 women (mean age 59.7 ± 17 years)). The primary reasons for admission to the hospital are listed in Table 1.

The median value of the GDS was 9 (IQR 4 -15), and women displayed higher values than men (median 11, IQR 5 -17 vs median 7, IQR 3 -13, p<0.001). The overall prevalence of depression (indicated by a GDS ≥ 15) was 26.1% (n=509). Table 2 shows the prevalence of subjects with (GDS ≥ 15) or without depression according to demographic characteristics, comorbid diseases, cognitive assessment, and degree of disability. Using this cut-off, the prevalence of depression was significantly higher in women (33.5%, n=330) than in men (18.6%, n=179, unadjusted OR 2.20; CI 95% 1.78 — 2.71). Depression was also high in patients with hypertension (OR 1.45; CI 95% 1.18-1.79), diabetes mellitus (OR 1.48, CI 95% 1.17-1.87), cerebrovascular disease (OR 1.50, CI 95% 1.08-2.07), and cirrhosis (OR 1.49, CI 95% 1.01-2.19). The median value of MMSE was significantly lower in patients with depression (28, IQR 26-30) than in patients without depression (30, IQR 27-30, unadjusted OR 0.92, CI 95% 0.88-0.96). Multivariate logistic regression analysis showed that the independent predictive factors for depression were age (adjusted OR 1.02, CI 95% 1.01-1.03), female gender (adjusted OR 2.17, CI 95% 1.62 - 2.91), and IADL (adjusted OR 0.86, CI 95% 0.79 - 0.93) (see Table 3).

Further, there was a mild but significant inverse correlation between GDS score and ADL (Spearman’s Rho = -0.18, p<0.001), IADL (Spearman’s Rho = -0.14; p<0.001), and MMSE (Spearman’s Rho = -0.15; p<0.001) (Figs. 1-3) and a positive correlation between GDS score and Charlson’s score (Spearman’s Rho = 0.13, p<0.001) (Fig. 4).

Table 1 Reasons for admission to hospital (n=1,947).

| Reasons for admission                       | n  | (%) |
|--------------------------------------------|----|-----|
| Diabetes Mellitus Impairment               | 192| (9.8)|
| Hypertensive Crisis                        | 170| (8.7)|
| Heart Failure                              | 127| (6.5)|
| Stroke or Transient Ischemic Attack        | 125| (6.4)|
| Pneumonia                                  | 105| (5.4)|
| Epigastrial Pain                           | 86 | (4.4)|
| Chronic Obstructive Pulmonary Disease      | 81 | (4.2)|
| Angina Pectoris                            | 70 | (3.6)|
| Cirrhosis                                  | 69 | (3.5)|
| Abdominal Pain                             | 51 | (2.6)|
| Cancer                                     | 47 | (2.4)|
| Fever                                      | 47 | (2.4)|
| Atrial Fibrillation                        | 44 | (2.3)|
| Anemia                                     | 43 | (2.2)|
| Renal Chronic Failure                      | 38 | (1.9)|
| Chronic Liver Disease                      | 33 | (1.7)|
| Arthrosis                                  | 31 | (1.6)|
| Syncope                                    | 19 | (1.0)|
| Dyspepsia                                  | 17 | (0.9)|
| Vertigo                                    | 16 | (0.8)|
| Claudicatio                                | 7  | (0.4)|
| Headache                                   | 6  | (0.3)|
| Others                                     | 523| (26.9)|

Figure 1  Correlation between Geriatric Depression Scale score and ADL score (Spearman’s Rho = - 0.18; p<0.001).
Table 2 Prevalence of depression (GDS ≥ 15) according to comorbidities.

|                                | Number of individuals (%) or mean ± SD* or median (IQR)§ | Subjects not depressed, with GDS < 15 (%) | Subjects depressed, with GDS > 15 (%) | Unadjusted odds ratio (95% CI) | p value |
|--------------------------------|-----------------------------------------------------------|------------------------------------------|--------------------------------------|-------------------------------|---------|
| Total study population         | 1947                                                      | 1438 (73.9)                              | 509 (26.1)                           | -                             |         |
| Age *                          | 59.8 ± 16                                                 | 58.36 ± 17                               | 64.0 ± 13                            | 1.02 (1.01-1.03)              | < 0.001 |
| Male                           | 961 (49.4)                                                | 782 (81.4)                               | 179 (18.6)                           | 2.20 (1.78-2.71)              | <0.001  |
| Hypertension                   | 671 (34.5)                                                | 463 (32.2)                               | 208 (40.9)                           | 1.45 (1.18-1.79)              | <0.001  |
| Diabetes mellitus              | 427 (21.9)                                                | 289 (20.1)                               | 138 (27.1)                           | 1.48 (1.17-1.87)              | <0.001  |
| Cerebrovascular disease        | 181 (9.3)                                                 | 120 (8.3)                                | 61 (12)                              | 1.50 (1.08-2.07)              | 0.021   |
| Cirrhosis                      | 124 (6.4)                                                 | 82 (5.7)                                 | 42 (8.3)                             | 1.49 (1.01-2.19)              | 0.044   |
| Heart Failure                  | 166 (8.5)                                                 | 118 (8.2)                                | 48 (9.4)                             | 1.16 (0.82-1.65)              | 0.396   |
| Coronary Artery Disease        | 224 (11.5)                                                | 155 (10.8)                               | 69 (13.6)                            | 1.30 (0.85-1.75)              | 0.092   |
| Chronic pulmonary disease      | 257 (13.2)                                                | 200 (13.9)                               | 57 (11.2)                            | 0.78 (0.57-1.07)              | 0.121   |
| Connective tissue disease      | 29 (1.5)                                                  | 20 (1.4)                                 | 9 (1.8)                              | 1.28 (0.58-2.82)              | 0.547   |
| Chronic renal disease          | 71 (3.6)                                                  | 46 (3.2)                                 | 25 (4.9)                             | 1.69 (1.01-2.82)              | 0.046   |
| Ulcer disease                  | 71 (3.6)                                                  | 55 (3.8)                                 | 16 (3.1)                             | 0.82 (0.46-1.43)              | 0.482   |
| Hypothyroidism                 | 22 (1.8)                                                  | 13 (1.5)                                 | 9 (2.5)                              | 1.77 (0.75-4.18)              | 0.19    |
| Hyperthyroidism                | 19 (1.5)                                                  | 13 (1.4)                                 | 6 (1.6)                              | 1.45 (1.18-1.79)              | <0.001  |
| Cancer                         | 102 (5.2)                                                 | 80 (5.6)                                 | 22 (4.3)                             | 0.96 (0.88-1.04)              | 0.28    |
| Charlson’s score§              | 1 (0-1)                                                   | 0 (0-1)                                  | 1 (0-1)                              | 1.04 (0.98-1.10)              | 0.21    |
| ADL §                          | 6 (6-6)                                                   | 6 (6-6)                                  | 6 (6-6)                              | 0.72 (0.63-0.82)              | <0.001  |
| IADL §                         | 8 (5-8)                                                   | 8 (6-8)                                  | 8 (4-8)                              | 0.83 (0.78-0.87)              | <0.001  |
| MMSE §                         | 29 (27-30)                                                | 30 (27-30)                               | 28 (26-30)                           | 0.92 (0.88-0.96)              | <0.001  |

Figure 2 Correlation between Geriatric Depression Scale score and IADL score (Spearman’s Rho = -0.14; p<0.001).

Figure 3 Correlation between Geriatric Depression Scale score and MMSE (Spearman’s Rho = -0.15; p<0.001).
According to the original definition by Brink and Yesavage, 706 patients (36.3%) had a GDS score between 10 and 20 (defined as "screened for mild depression"), and 205 patients (10.5%) had a score equal to or greater than 20 (defined as "screened for severe depression"). In the overall study population, 188 patients (9.6%) reported a prior diagnosis of depression, 23 (1.1%) a diagnosis of major depression, and 55 (2.8%) generic "depressive symptoms". In the group of 509 patients with a GDS score \( \geq 15 \), 113 subjects (22.2%) reported a prior diagnosis of depression (including all definitions) and 28 (5.5%) reported a prior diagnosis of anxiety. Fifteen subjects (2.9% of 509) reported a previous diagnosis of "depression major", 37 (7.3%) a generic "depression syndrome", and 70 (13.8%) were previously classified as having an "anxiety-depressive syndrome" (Table 4). Analyzing the group of patients screened for "severe depression" (205 subjects with GDS \( \geq 20 \)), 57 (27.8%) reported a prior diagnosis of depression (indicated with any definition).

Overall, 95 patients (4.8%) reported taking antidepressant drugs prior to hospital admission: 25 (1.3%) tricyclic antidepressants and 70 (3.6%) selective serotonin reuptake inhibitors (SSRI). Analyzing the group of depressed patients identified by GDS score \( \geq 15 \), 59 patients (11.6%) used antidepressants: 19 tricyclic (3.7%), and 40 (7.9%) SSRI. Within the group of patients screened for "severe depression" (GDS \( \geq 20 \)), 24 (11.7%) used antidepressants: 9 tricyclic and 15 SSRI (Table 5). None of patients reported other types of treatment for depression (e.g., psychotherapy, psychoanalysis).

### Table 3

| Factor                               | Odd Ratio | CI 95%   | p   |
|--------------------------------------|-----------|----------|-----|
| Age                                  | 1.02      | 1.01 - 1.02 | 0.00|
| Gender (female)                      | 2.29      | 1.83 - 2.87 | 0.00|
| Hypertension                         | 1.13      | 0.89 - 1.43 | 0.33|
| Diabetes mellitus                    | 1.86      | 0.98 - 3.52 | 0.06|
| Cerebropathy                         | 1.89      | 0.90 - 3.95 | 0.09|
| Cirrhosis                            | 5.62      | 0.92 - 34.34 | 0.06|
| Heart Failure                        | 0.85      | 0.58 - 1.26 | 0.42|
| Coronary Artery Disease              | 1.02      | 0.72 - 1.44 | 0.91|
| Chronic pulmonary disease            | 1.17      | 0.60 - 2.28 | 0.65|
| Connective tissue disease            | 1.83      | 0.66 - 5.09 | 0.24|
| Chronic renal disease                | 3.17      | 0.87 - 11.58 | 0.08|
| Ulcer disease                        | 1.36      | 0.59 - 3.12 | 0.48|
| Hypothyroidism                       | 1.40      | 0.56 - 3.50 | 0.47|
| Hyperthyroidism                      | 1.33      | 0.48 - 3.67 | 0.59|
| Cancer                               | 1.40      | 0.77 - 2.53 | 0.27|
| ADL                                  | 0.87      | 0.74 - 1.04 | 0.12|
| IADL                                 | 0.86      | 0.81 - 0.93 | 0.00|
| MMSE                                 | 0.99      | 0.95 - 1.04 | 0.68|
| Charlson’s score                     | 0.65      | 0.36 - 1.18 | 0.16|

### Table 4

| Diagnosis                          | Number of individuals (%) | Subjects not depressed, with GDS < 15 N (%) | Subjects depressed, with GDS > 15 N (%) | p     |
|------------------------------------|---------------------------|---------------------------------------------|------------------------------------------|-------|
| Total study population             | 1947                      | 1438 (73.9)                                 | 509 (26.1)                               | -     |
| Depression Major                   | 23 (1.2)                  | 15 (0.6)                                    | 23 (2.9)                                 | <0.001|
| Depressive syndrome                | 55 (2.8)                  | 18 (1.3)                                    | 37 (7.3)                                 | <0.001|
| Anxiety-depressive syndrome        | 119 (6.1)                 | 49 (3.4)                                    | 70 (13.8)                                | <0.001|
| Depression (sum of all definitions)| 188 (9.7)                 | 75 (5.2)                                    | 113 (22.2)                               | <0.001|
| Use of Tricyclic                   | 25 (1.3)                  | 6 (0.4)                                     | 19 (3.7)                                 | <0.001|
| Use of SSRI                        | 70 (3.6)                  | 30 (2.1)                                    | 40 (7.9)                                 | <0.001|
In recent years, many issues have been raised on the significance of concomitant depression and comorbidities; however, few data are available on the rate and distribution of depression in large samples of unselected patients hospitalized in Internal Medicine wards.

The primary objectives of the current study were to evaluate the prevalence of depressive symptoms among medical inpatients and the association between these symptoms and the demographic, pathological and functional characteristics of the patients.

In the present survey, the GDS was used to classify patients as depressed or not depressed. This could be considered as a limitation of the study because DSM-IV criteria are typically utilized to diagnose clinical depression. However, the GDS has been used for large studies, and although it was developed for elderly patients, it has also been validated as a screening tool for depressive symptoms in younger subjects [36,37]. Previous studies in hospitalized patients indicated that GDS does not maintain its validity in populations with large numbers of cognitively impaired patients [42,43].

Therefore, the current survey excluded patients with a significant cognitive impairment (Mini-Mental State Examination < 22). Further, in order to reduce the influence of hospitalization on the patient’s mood and therefore on the GDS score, patients who did not complete the examination within 24 hours of admission to the hospital were excluded. Based on these perspectives, the GDS may be considered as a reliable test for the purposes of the study.

Based on previous literature [33,38], patients with a GDS score ≥ 15 were labeled as “depressed”. By using this cutoff, we observed a prevalence of 26% of depressed patients. Moreover, on the basis of the original scoring by Brink and Yesavage [32], 46.8% of the subjects exhibited a GDS score ≥ 10 (“mild” or “severe depressives”). These data are consistent with previous studies that indicated a high prevalence of depression in patients with comorbidities. In particular, Freedland et al. observed that in a cohort of hospitalized patients affected with heart failure, 20% met the DSM-IV criteria for a current major depressive episode, 16% for a minor depressive episode, and 51% scored above the cut-off for depression on the Beck Depression Inventory [5].

The current findings suggest that the diagnosis of depression is largely underestimated. In the present sample, only 22.2% of subjects with a GDS score ≥ 15 were previously classified as depressed and only 11.6% were taking antidepressants prior to hospitalization. Analyzing the group of patients with a GDS score ≥ 20, the rate of patients with a previous diagnosis of depression remained low (27.8%) and only 11.7% reported prior treatment with antidepressants. As a consequence, approximately 90% of patients who were candidates to receive therapy for depression were not treated. These findings confirm other recent data that indicated an under use of antidepressants [44].

The current results indicate that elderly subjects, women, and patients with loss of autonomy have a significantly higher risk of depression. Although patients with hypertension, diabetes mellitus, cerebrovascular disease, or cirrhosis showed raised unadjusted odds ratio for depression, the multivariate analysis indicated that the independent risk factors for depression were age, gender (female) and IADL. Moreover, the study did not find a significant association between cancer and depression. The present data are consistent with other large surveys that showed high variability in the prevalence of depression in patients with cancer [45–47].

The study aimed to determine whether depression is related to the overall burden of comorbidity. To evaluate this issue, the Charlson’s Comorbidity Index was used. The data indicate a mild correlation between Charlson’s score and GDS score; however, this association was not confirmed in the multivariate analysis. This finding suggests that depression is not related to the severity of comorbidity (Charlson’s score), but is more closely related to loss of autonomy and disability (IADL). This association has been suggested by other recent studies that indicated the role of severe functional impairment in determining post-stroke depression [48,49] and the correlation between depression and disability in a large sample of adults living in households [50].

### Conclusions

In the present study, a high prevalence of depressive symptoms was found among patients hospitalized in Internal Medicine Units. Depressive symptoms were not independently related to the severity of concomitant diseases (Charlson’s score), but were associated with the loss of autonomy for IADL. The data, showing a significant grade of under-diagnosis and under-treatment of depressive symptoms, suggest that physicians working in Internal Medicine Departments should take account of this condition and
consider introducing the mood evaluation into routine clinical practice. This approach may be justified as identifying and treating depression at early stages may have positive effects on clinical evolution and quality of life. Future studies are needed to further investigate the prognostic impact of concomitant depression and comorbidities and the role of specific treatments to improve patients’ mood and clinical outcome.

Conflict of interest statement

The authors have no conflict of interest.

Acknowledgments

The authors thank Erminio Bonizzoni, PhD (Institute of Medical Statistics and Biometry, University of Milan, Milan, Italy) for useful discussions and comments on the statistical analyses.

Researchers of the DIMIS study and FADOI centers:
C. Ciffo, S. Pagano, A. Strazzanti, (Hospital of Piazza Armerina), M. Manfrè, R. Adamo, (Hospital of Patti), V. Ventura, A. Gambino (Hospital of Barcellona Pozzo di Gotto), F. Di Blasi, P. Venuto (Hospital of Milazzo), V. Vannini (Hospital of Modica), G. Calcara, (Hospital of Acireale), B. Condorelli, G. Perracchio (Vittorio Emanuele Hospital, Catania), M. Augugliaro, G. Di Nolfo (Hospital of Petralia Sottana), L. Florio (Buccheri-La Ferla Fatebenfratelli Hospital, Caltagirone), P. Hamel, G. Pistone, F. Lanzarone, S. Lombardo (Civico Hospital, Palermo), A. Bajardi, G. Ingarao, L. Totani (Ingrassia Hospital, Palermo), G. A. Puglia, M. Petruso, F. Savaia, (Hospital of Termini Imprese), P. Mellone, G. Pistone, F. Lanzarone, S. Lombardo (Civico Hospital, Palermo), L. Florio (Buccheri-La Ferla Fatebenfratelli Hospital, Palermo), C. Corradino, C. Muratori (University of Palermo), C. Polizzi, F. Pantaleo, R. Cangelosi (Hospital of Marsala), L. Battista, C. Eufrate, A. Pulone, G. Pumilia (Villa Sofia Whitaker Hospital, Palermo).

References

[1] WHO International Consortium in Psychiatric Epidemiology. Cross-national comparisons of prevalences and correlates of mental disorders. Bull World Health Organ 2000;78(4):413—26.
[2] Sobocki P, Jonsson B, Angst J, Rehnberg C. Cost of depression in Europe. J Ment Health Policy Econ 2006;9(2):87—98.
[3] Berardi D, Leggieri G, Ceroni GB, Rucci P, Pezzoli A, Paltrinieri E, et al. Depression in primary care. A nationwide epidemiological survey. Family Practice 2002;19:397—400.
[4] de Girolamo G, Poldori G, Morosini P, Scarpino V, Reda V, Serra G, et al. Prevalence of common mental disorders in Italy: results from the European Study of the Epidemiology of Mental Disorders (ESEMed). Soc Psychiatry Psychiatr Epidemiol 2006;41(11):853—61.
[5] Freedland KE, Rich MW, Skala JA, Carney RM, Davila-Roman VG, Jaffe AS. Prevalence of depression in hospitalized patients with congestive heart failure. Psychosom Med 2003;65:119—28.
[6] Aragonès E, Pihol JL, Labad A. Depression and physical comorbidity in primary care. J Psychosom Res 2007;63(2):107—11.
[7] Barossi C, Shaffer J, Sattler S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007;3(370 (9590)):851—8.
[8] Mallik S, Krumholz HM, Lin QZ, Kasl SV, Mattera JR, Roumains SA, et al. Patients with depressive symptoms have lower health status benefits after coronary artery bypass surgery. Circulation 2005;111(3):271—7.
[9] Sullivan MD, Newton K, Hecht J, Russo JE, Spertus JA. Depression and health status in elderly patients with heart failure: a 6-month prospective study in primary care. Am J Geriatr Cardiol 2004;13(5):252—60.
[10] Koening HG. Depression outcome in inpatients with congestive heart failure. Arch Intern Med 2006;166(9):991—6.
[11] Bremmer MA, Hoogendijk WJ, Deeg DJ, Schoevers RA, Schalk BW, Beekman AT. Depression in older age is a risk factor for first ischemic cardiac events. Am J Geriatr Psychiatry 2006;14(6):523—30.
[12] Engum A. The role of depression and anxiety in onset of diabetes in a large population-based study. J Psychosom Res 2007;62(1):31—8.
[13] Frasure-Smith N, Lepersance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1995;91:999—1005.
[14] Covinsky KE, Kahana E, Chinn MH, Palmer RW, Fortinsky RH, Landefeld CS. Depressive symptoms and 3-year mortality in older hospitalized medical patients. Ann Intern Med 1999;6(130(7)):563—9.
[15] Schulz R, Beach SR, Ives DG, Martire LM, Ariyo AA, Kop WJ. Association between depression and mortality in older adults: the cardiovascular health study. Arch Intern Med 2000;160:1761—8.
[16] Kamphuis MH, Kalmijn S, Tijhuis MA, Geerdink EA, Nisues N, Nisues A, et al. Depressive symptoms as risk factor of cardiovascular mortality in older European men: the Finland, Italy and Netherlands Elderly (FINE) study. Eur J Cardiovasc Prev Rehabil 2006;13(2):199—206.
[17] Jiang W, Kuchibhatla M, Clary GL, Cuffe MS, Christopher EJ, Alexander JD, et al. Relationship between depressive symptoms and long-term mortality in patients with heart failure. Am Heart J 2007;154(1):102—8.
[18] McGuire J, Cole MJ, Lamb A, Latimer E, Windholz S, Belizie E. Does depression in older medical inpatients predict mortality? J Gerontol A Biol Sci Med Sci 2006;61(9):975—81.
[19] Dickens C, McGowan L, Percival C, Tomenson B, Cotter L, Heagerty A, et al. Depression is a risk factor for mortality after myocardial infarction: fact or artifact? J Am Coll Cardiol 2007;49(18):1834—40.
[20] Covinsky KE, Kahana E, Chin MH, Palmer RW, Fortinsky RH, Landefeld CS. Depressive symptoms and 3-year mortality in older hospitalized medical patients. Ann Intern Med 1999;6(130(7)):563—9.
[21] Ferketich AK, Ferguson JP, Binkley PF. Depressive symptoms and inflammation among heart failure patients. Am Heart J 2005;150(1):132—6.
[22] Pizzi C, Manzoli L, Mancini S, Costa GM. Analysis of potential predictors of depression among coronary heart disease risk factors including heart rate variability, markers of inflammation, and endothelial function. Eur Heart J 2007;28(9):1110—7.
[23] Pignone MP, Gaynes BN, Rushton JL, Burchell CM, Orleans CT, Mulrow CD, et al. Screening for depression in adults: a summary

Depressive symptoms and disability in acute patients with comorbidities in departments of internal medicine 267
of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136(10):765—76.

[24] Johansson P, Dahlstrom U, Brostrom A. The measurement and prevalence of depression in patients with chronic heart failure. Prog Cardiovasc Nurs 2006;21(1):28—36.

[25] Glassman AH, O’Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger Jr JT, et al., Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002;288:701—9.

[26] van den Brink RH, van Melle JP, Honig A, Schene AH, Crijns HJ, Lambert FP, et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial Infarction and Depression-Intervention Trial (MIND-IT). Am Heart J 2002;144:219—25.

[27] Robinson RG, Jorge RE, Moser DJ, Acion L, Solodkin A, Small SL, et al. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. JAMA 2008 May 28;299(20):2391—400.

[28] Penn JV, Boland R, McCartney JR, Kohn R, Mulvey T. Recognition and treatment of depressive disorders by internal medicine attendings and housestaff. Gen Hosp Psychiatry 1997;19(3):179—84.

[29] Folstein MF, Robins LN, Helzer JE. The Mini-Mental State Examination. Arch Gen Psychiatry 1983.

[30] Kukull WA. The Mini-Mental State Examination score and the clinical diagnosis of dementia. J Clin Epidemiol 1994;47(9):1061—7.

[31] Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiat Res 1982-1983;17:37—49.

[32] Brink TL, Yesavage JA, Lum O, Heersema P, Adey MB, Rose TL. Screening tests for geriatric depression. Clin Gerontologist 1982;1:37—44.

[33] Ertan FS, Ertan T, Kiziltan G, Uyguc, Zgourides G, Spofford M, Doppett L. The Geriatric Depression Scale: discriminant validity and elderly day-treatment clients. Psychol Rep 1989;64:1082.

[34] Ferraoro FR, Chelminski IJ. Preliminary normative data on the Geriatric Depression Scale-Short Form (GDS-SF) in a young adult sample. J Clin Psychol 1996;52(4):443—7.

[35] Zgourides G, Spofford M, Doppett L. The Geriatric Depression Scale: a sensitive and convenient instrument for measuring depression in young anorexic patients. J Nerv Ment Dis 2001;189(5):338—9.

[36] Weintraub D, Saboe K, Stern MB. Effect of age on geriatric depression scale performance in Parkinson’s disease. Mov Disord 2007;22(9):1331—5.

[37] Zalsman G, Weizman A, Carel CA, Aizenberg D. Geriatric Depression Scale (GDS-15): a sensitive and convenient instrument for measuring depression in young anorexic patients. J Nerv Ment Dis 2001;189(5):338—9.

[38] Weitnraub D, Saboe K, Stern MB. Effect of age on geriatric depression scale performance in Parkinson’s disease. Mov Disord 2007;22(9):1331—5.

[39] Charlson ME, Pompei P. Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373—83.

[40] Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The Index of ADL: A standardized measure of biological and psychosocial function. JAMA 1982;185:914—9.

[41] Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9(3):179—86.

[42] Anthony J, LeResche L, Niaz U, Von Korff J, Folstein M. Limits of the “Mini-Mental State Exam” as a screening test for dementia and delirium among hospitalized patients. Psychol Med 1982;12:397—408.

[43] Burke WJ, Nitcher RL, Roccaforte WH, Wengel SP. A prospective evaluation of the Geriatric Depression Scale in an outpatient geriatric assessment center. J Am Geriatr Soc 1992;40:1227—30.

[44] Paul SL, Dewey HM, Sturm JW, Macdonell RA, Thirlt AG. Prevalence of Depression and Use of Antidepressant Medication at 5-Years Poststroke in the North East Melbourne Stroke Incidence Study. Stroke 2006 Nov;37(11):2854—5.

[45] Dalton SO, Mellemkjær L, Olsen JH, Mortensen PB, Johansen C. Depression and cancer risk: a register-based study of patients hospitalized with affective disorders, Denmark, 1969—1993. Am J Epidemiol 2002;155(12):1088—95.

[46] Pasquini M, Biondi M. Depression in cancer patients: a critical review. Clin Pract Epidemiol Ment Health 2007;3:2.

[47] Wedding U, Koch A, Röhrig B, Pientka L, Sauer H, Hoffken K, et al. Depression and functional impairment independently contribute to decreased quality of life in cancer patients prior to chemotherapy. Acta Oncol 2008;47(1):56—62.

[48] van de Port IG, Kwakkel G, Bruin M, Lindeman E. Determinants of depression in chronic stroke: a prospective cohort study. Disabil Rehabil 2007;29(5):353—8.

[49] Provinciali L, Paolucci S, Torta R, Toso V, Gobbi B, Gandolfo C. Depression after First-Ever Ischemic Stroke: The Prognostic Role of Neuroanatomic Subtypes in Clinical Practice. Cerebrovasc Dis 2008 Oct 23;26(6):592—9.

[50] Merikangas KR, Ames M, Cui L, Stang PE, Ustun B, Von Korff M, et al. The impact of comorbidity of Mental and Physical conditions on Role Disability in the US Adult Household Population. Arch Gen Psychiatry 2007;64(10):1180—8.